{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:43:43Z","timestamp":1790700223469,"version":"4.1.0"},"reference-count":39,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"DOI":"10.31744\/einstein_journal\/2024rc1107","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T14:20:36Z","timestamp":1732717236000},"source":"Crossref","is-referenced-by-count":7,"title":["Beyond the rare: a case of pseudomyogenic hemangioendothelioma treated sequentially with everolimus, denosumab, and pazopanib"],"prefix":"10.31744","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9536-6504","authenticated-orcid":false,"given":"Douglas Dias e","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5217-6237","authenticated-orcid":false,"given":"Camila Bobato Lara","family":"Gismondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-5649","authenticated-orcid":false,"given":"Murilo Marques Almeida","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-1183","authenticated-orcid":false,"given":"Renee Zon","family":"Filipi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-1544","authenticated-orcid":false,"given":"Fernando","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-5729","authenticated-orcid":false,"given":"Reynaldo","family":"Jesus-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1141-7608","authenticated-orcid":false,"given":"Roberto Carmagnani","family":"Pestana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"issue":"2","key":"key20241127142025_B1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/PAS.0b013e3181ff0901","article-title":"Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior","volume":"35","author":"Hornick","year":"2011","unstructured":"Hornick JL, Fletcher CD. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol. 2011;35(2):190-201.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"key20241127142025_B2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/1097-0142(19920315)69:6<1382::AID-CNCR2820690614>3.0.CO;2-Y","article-title":"The fibroma-like variant of epithelioid sarcoma. A fibrohistiocytic\/myoid cell lesion often confused with benign and malignant spindle cell tumors","volume":"69","author":"Mirra","year":"1992","unstructured":"Mirra JM, Kessler S, Bhuta S, Eckardt J. The fibroma-like variant of epithelioid sarcoma. A fibrohistiocytic\/myoid cell lesion often confused with benign and malignant spindle cell tumors. Cancer. 1992;69(6):1382-95.","journal-title":"Cancer"},{"key":"key20241127142025_B3","doi-asserted-by":"crossref","first-page":"107639","DOI":"10.1016\/j.ijscr.2022.107639","article-title":"Pseudomyogenic hemangioendothelioma: a misleading vascular tumor","volume":"99","author":"Sassi","year":"2022","unstructured":"Sassi F, Sahraoui G, Charfi L, Jaidane O, Mrad K, Doghri R. Pseudomyogenic hemangioendothelioma: a misleading vascular tumor. Int J Surg Case Rep. 2022;99(August):107639.","journal-title":"Int J Surg Case Rep"},{"issue":"5","key":"key20241127142025_B4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/DAD.0b013e31827c8051","article-title":"Pseudomyogenic hemangioendothelioma: report of an additional case with aggressive clinical course","volume":"35","author":"Sheng","year":"2013","unstructured":"Sheng W, Pan Y, Wang J. Pseudomyogenic hemangioendothelioma: report of an additional case with aggressive clinical course. Am J Dermatopathol. 2013;35(5):597-600.","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"key20241127142025_B5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1186\/s12885-018-4934-0","article-title":"Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study","volume":"18","author":"Shiba","year":"2018","unstructured":"Shiba S, Imaoka H, Shioji K, Suzuki E, Horiguchi S, Terashima T, et al. Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study. BMC Cancer. 2018;18(1):993.","journal-title":"BMC Cancer"},{"issue":"10","key":"key20241127142025_B6","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.radcr.2019.06.029","article-title":"Pseudomyogenic hemangioendothelioma-A case report and review of the literature","volume":"14","author":"Dianat","year":"2019","unstructured":"Dianat S, Yousaf H, Murugan P, Marette S. Pseudomyogenic hemangioendothelioma-A case report and review of the literature. Radiol Case Rep. 2019;14(10):1228-32.","journal-title":"Radiol Case Rep"},{"issue":"5","key":"key20241127142025_B7","first-page":"38","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"2013","author":"Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep. 2013;2013(5):38-43.","journal-title":"BMJ Case Rep"},{"issue":"3","key":"key20241127142025_B8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.path.2015.05.001","article-title":"Diagnostically Challenging Epithelioid Vascular Tumors","volume":"8","author":"Ko","year":"2015","unstructured":"Ko JS, Billings SD. Diagnostically Challenging Epithelioid Vascular Tumors. Surg Pathol Clin. 2015;8(3):331-51.","journal-title":"Surg Pathol Clin"},{"issue":"16","key":"key20241127142025_B9","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/cncr.33618","article-title":"Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities","volume":"127","author":"Stacchiotti","year":"2021","unstructured":"Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bov\u00e9e JV, et al. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021;127(16):2934-42.","journal-title":"Cancer"},{"key":"key20241127142025_B10","volume-title":"Retrospective observational studies in ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments","author":"Stacchiotti","year":"2022","unstructured":"Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, et al. Retrospective observational studies in ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Vol. 110. W.B. Saunders Ltd: Cancer Treatment Reviews; 2022."},{"issue":"1","key":"key20241127142025_B11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00000478-200301000-00006","article-title":"Epithelioid sarcoma-like hemangioendothelioma","volume":"27","author":"Billings","year":"2003","unstructured":"Billings SD, Folpe AL, Weiss SW. Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol. 2003;27(1):48-57.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"key20241127142025_B12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.path.2015.05.001","article-title":"Diagnostically challenging epithelioid vascular tumors","volume":"8","author":"Ko","year":"2015","unstructured":"Ko JS, Billings SD. Diagnostically challenging epithelioid vascular tumors. Surg Pathol Clin. 2015;8(3):331-51.","journal-title":"Surg Pathol Clin"},{"issue":"6","key":"key20241127142025_B13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.5858\/arpa.2017-0430-RS","article-title":"Pseudomyogenic Hemangioendothelioma","volume":"143","author":"Al-Qaderi","year":"2019","unstructured":"Al-Qaderi A, Mansour AT. Pseudomyogenic Hemangioendothelioma. Arch Pathol Lab Med. 2019;143(6):763-7.","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"key20241127142025_B14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00428-020-02753-4","article-title":"The clinicopathological spectrum of pseudomyogenic hemangioendothelioma: report of an additional series with review of the literature","volume":"477","author":"Sun","year":"2020","unstructured":"Sun Y, Zhao M, Lao IW, Yu L, Wang J. The clinicopathological spectrum of pseudomyogenic hemangioendothelioma: report of an additional series with review of the literature. Virchows Arch. 2020;477(2):231-40.","journal-title":"Virchows Arch"},{"issue":"5","key":"key20241127142025_B15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/PAS.0000000000000613","article-title":"Primary Pseudomyogenic Hemangioendothelioma of Bone","volume":"40","author":"Inyang","year":"2016","unstructured":"Inyang A, Mertens F, Puls F, Sumathi V, Inwards C, Folpe A, et al. Primary Pseudomyogenic Hemangioendothelioma of Bone. Am J Surg Pathol. 2016; 40(5):587-98.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"key20241127142025_B16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11657-022-01062-4","article-title":"Pseudomyogenic hemangioendothelioma with bone and soft tissue involvement with favorable response to pamidronate: a case report and systematic review of the literature","volume":"17","author":"Brance","year":"2022","unstructured":"Brance ML, C\u00f3ccaro NM, Roitman P, Castiglioni A, Agostinis F, Spense M, et al. Pseudomyogenic hemangioendothelioma with bone and soft tissue involvement with favorable response to pamidronate: a case report and systematic review of the literature. Arch Osteoporos. 2022;17(1):28.","journal-title":"Arch Osteoporos"},{"issue":"4","key":"key20241127142025_B17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cancergen.2011.01.002","article-title":"Translocation t(7;19)(q22;q13)\u2212a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma?","volume":"204","author":"Trombetta","year":"2011","unstructured":"Trombetta D, Magnusson L, von Steyern FV, Hornick JL, Fletcher CD, Mertens F. Translocation t(7;19)(q22;q13)\u2212a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma? Cancer Genet. 2011;204(4):211-5.","journal-title":"Cancer Genet"},{"issue":"5","key":"key20241127142025_B18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/path.4322","article-title":"A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma","volume":"232","author":"Walther","year":"2014","unstructured":"Walther C, Tayebwa J, Lilljebj\u00f6rn H, Magnusson L, Nilsson J, von Steyern FV, et al. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma. J Pathol. 2014;232(5):534-40.","journal-title":"J Pathol"},{"issue":"5","key":"key20241127142025_B19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41379-018-0175-7","article-title":"Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma","volume":"32","author":"Zhu","year":"2019","unstructured":"Zhu G, Benayed R, Ho C, Mullaney K, Sukhadia P, Rios K, et al. Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol. 2019;32(5):609-20.","journal-title":"Mod Pathol"},{"issue":"4","key":"key20241127142025_B20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.21873\/cgp.20134","article-title":"Fusion of the Genes WWTR1 and FOSB in Pseudomyogenic Hemangioendothelioma","volume":"16","author":"Panagopoulos","year":"2019","unstructured":"Panagopoulos I, Lobmaier I, Gorunova L, Heim S. Fusion of the Genes WWTR1 and FOSB in Pseudomyogenic Hemangioendothelioma. Cancer Genomics Proteomics. 2019;16(4):293-8.","journal-title":"Cancer Genomics Proteomics"},{"issue":"1","key":"key20241127142025_B21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/gcc.22891","article-title":"A novel CLTC-FOSB gene fusion in pseudomyogenic hemangioendothelioma of bone","volume":"60","author":"Bridge","year":"2021","unstructured":"Bridge JA, Sumegi J, Royce T, Baker M, Linos K. A novel CLTC-FOSB gene fusion in pseudomyogenic hemangioendothelioma of bone. Genes Chromosomes Cancer. 2021;60(1):38-42.","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"key20241127142025_B22","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/his.14349","article-title":"Novel EGFL7-FOSB fusion in pseudomyogenic haemangioendothelioma with widely metastatic disease","volume":"79","author":"Hakar","year":"2021","unstructured":"Hakar MH, White K, Hansford BG, Swensen J, Davis JL. Novel EGFL7-FOSB fusion in pseudomyogenic haemangioendothelioma with widely metastatic disease. Histopathology. 2021;79(5):888-91.","journal-title":"Histopathology"},{"issue":"3","key":"key20241127142025_B23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/his.14697","article-title":"Primary pseudomyogenic haemangioendothelioma of the testis with a novel POTEI:FOSB gene fusion","volume":"81","author":"Gersmann","year":"2022","unstructured":"Gersmann AK, Haller F, Behnert N, Richter A, St\u00f6hr R, Hartmann A, et al. Primary pseudomyogenic haemangioendothelioma of the testis with a novel POTEI:FOSB gene fusion. Histopathology. 2022;81(3):411-4.","journal-title":"Histopathology"},{"issue":"5","key":"key20241127142025_B24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/1097-0142(19820901)50:5<970::AID-CNCR2820500527>3.0.CO;2-Z","article-title":"Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma","volume":"50","author":"Weiss","year":"1982","unstructured":"Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer. 1982;50(5):970-81.","journal-title":"Cancer"},{"key":"key20241127142025_B25","first-page":"22","volume-title":"Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma","author":"Joseph","year":"2015","unstructured":"Joseph J, Wang WL, Patnana M, Ramesh N, Benjamin R, Patel S, et al. Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. Vol. 5, England: Clinical sarcoma research; 2015. p. 22."},{"issue":"6","key":"key20241127142025_B26","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1097\/MPH.0000000000000778","article-title":"Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma","volume":"39","author":"Ozeki","year":"2017","unstructured":"Ozeki M, Nozawa A, Kanda K, Hori T, Nagano A, Shimada A, et al. Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma. J Pediatr Hematol Oncol. 2017;39(6):e328-31.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"key20241127142025_B27","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12725","article-title":"The management of pseudomyogenic hemangioendothelioma of the foot: a case report and review of the literature","volume":"31","author":"Pranteda","year":"2018","unstructured":"Pranteda G, Magri F, Muscianese M, Pigliacelli F, D\u2019Arino A, Federico A, et al. The management of pseudomyogenic hemangioendothelioma of the foot: a case report and review of the literature. Dermatol Ther. 2018;31(6):e12725.","journal-title":"Dermatol Ther"},{"issue":"1","key":"key20241127142025_B28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1186\/s12885-019-6072-8","article-title":"Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report","volume":"19","author":"Otani","year":"2019","unstructured":"Otani S, Nakayama R, Sekita T, Hirozane T, Asano N, Nishimoto K, et al. Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report. BMC Cancer. 2019;19(1):872.","journal-title":"BMC Cancer"},{"issue":"3","key":"key20241127142025_B29","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4103\/jcrt.JCRT_1138_20","article-title":"Multifocal primary pseudomyogenic hemangioendothelioma of bone managed with denosumab: A rare case with diagnostic and therapeutic challenge","volume":"18","author":"Pasricha","year":"2022","unstructured":"Pasricha S, Sharma A, Pruthi M, Durga G, Jajodia A, Gupta G, et al. Multifocal primary pseudomyogenic hemangioendothelioma of bone managed with denosumab: A rare case with diagnostic and therapeutic challenge. J Cancer Res Ther. 2022;18(3):817-9.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"key20241127142025_B30","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26781","article-title":"Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma","volume":"65","author":"Gabor","year":"2018","unstructured":"Gabor KM, Sapi Z, Tiszlavicz LG, Fige A, Bereczki C, Bartyik K. Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma. Pediatr Blood Cancer. 2018;65(2):e26781.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"key20241127142025_B31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MPH.0000000000001459","article-title":"Effective Use of Sirolimus and Zoledronic Acid for Multiosteotic Pseudomyogenic Hemangioendothelioma of the Bone in a Child: Case Report and Review of Literature","volume":"41","author":"Danforth","year":"2019","unstructured":"Danforth OM, Tamulonis K, Vavra K, Oh C, Brickman A, Ebersole J, et al. Effective Use of Sirolimus and Zoledronic Acid for Multiosteotic Pseudomyogenic Hemangioendothelioma of the Bone in a Child: Case Report and Review of Literature. J Pediatr Hematol Oncol. 2019;41(5):382-7.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"key20241127142025_B32","article-title":"Pazopanib as Treatment Option for Pseudomyogenic Hemangioendothelioma: a Case Report","volume":"14","author":"Alhanash","year":"2022","unstructured":"Alhanash A, Aseafan M, Atallah J. Pazopanib as Treatment Option for Pseudomyogenic Hemangioendothelioma: a Case Report. Cureus. 2022; 14(5):e25250.","journal-title":"Cureus"},{"issue":"11","key":"key20241127142025_B33","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1158\/1078-0432.CCR-17-3512","article-title":"Telatinib is an effective targeted therapy for pseudomyogenic hemangioendothelioma","volume":"24","author":"van IJzendoorn","year":"2018","unstructured":"van IJzendoorn DG, Sleijfer S, Gelderblom H, Eskens FA, van Leenders GJ, Szuhai K, et al. Telatinib is an effective targeted therapy for pseudomyogenic hemangioendothelioma. Clin Cancer Res. 2018;24(11):2678-87.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"key20241127142025_B34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/cac2.12020","article-title":"Clinicopathological features of pseudomyogenic hemangioendothelioma and precision therapy based on whole exome sequencing","volume":"40","author":"Wei","year":"2020","unstructured":"Wei J, Liao Z, Zhao G, Nahar N, Zhang C, Lu J, et al. Clinicopathological features of pseudomyogenic hemangioendothelioma and precision therapy based on whole exome sequencing. Cancer Commun (Lond). 2020;40(4):197-201.","journal-title":"Cancer Commun (Lond)"},{"issue":"55","key":"key20241127142025_B35","doi-asserted-by":"crossref","first-page":"95023","DOI":"10.18632\/oncotarget.21832","article-title":"The benefit of everolimus in recurrent\/epithelioid angiosarcoma patients: case reports and literature review","volume":"8","author":"Zhang","year":"2017","unstructured":"Zhang SL, Liang L, Ji Y, Wang ZM, Zhou YH. The benefit of everolimus in recurrent\/epithelioid angiosarcoma patients: case reports and literature review. Oncotarget. 2017;8(55):95023-9.","journal-title":"Oncotarget"},{"issue":"8","key":"key20241127142025_B36","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1634\/theoncologist.12-8-1007","article-title":"The biology behind mTOR inhibition in sarcoma","volume":"12","author":"Wan","year":"2007","unstructured":"Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007;12(8):1007-18.","journal-title":"Oncologist"},{"issue":"1","key":"key20241127142025_B37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13000-019-0857-6","article-title":"A rare case of pseudomyogenic hemangioendothelioma (PHE)\/epithelioid sarcoma-like hemangioendothelioma (ES-H) of the breast first misdiagnosed as metaplastic carcinoma by FNAB and review of the literature","volume":"14","author":"Ge","year":"2019","unstructured":"Ge Y, Lin X, Zhang F, Xu F, Luo L, Huang W, et al. A rare case of pseudomyogenic hemangioendothelioma (PHE)\/epithelioid sarcoma-like hemangioendothelioma (ES-H) of the breast first misdiagnosed as metaplastic carcinoma by FNAB and review of the literature. Diagn Pathol. 2019;14(1):79. Review.","journal-title":"Diagn Pathol"},{"issue":"5","key":"key20241127142025_B38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","unstructured":"Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577-90.","journal-title":"Cell"},{"issue":"October","key":"key20241127142025_B39","doi-asserted-by":"crossref","first-page":"580605","DOI":"10.3389\/fonc.2020.580605","article-title":"Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls","volume":"10","author":"Li","year":"2020","unstructured":"Li H, Gao J, Gao Y, Lin N, Zheng M, Ye Z. Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls. Front Oncol. 2020;10(October):580605.","journal-title":"Front Oncol"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T14:20:48Z","timestamp":1732717248000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/beyond-the-rare-a-case-of-pseudomyogenic-hemangioendothelioma-treated-sequentially-with-everolimus-denosumab-and-pazopanib\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":39,"alternative-id":["10.31744\/einstein_journal\/2024RC1107"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2024rc1107","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"eRC1107"}}